We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+7.61%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$175M
AUM Growth
+$9.44M
Cap. Flow
+$6.42M
Cap. Flow %
3.67%
Top 10 Hldgs %
36.64%
Holding
129
New
19
Increased
30
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
NLSN
Nielsen Holdings plc
NLSN
+$2.98M
2
BKI
Black Knight, Inc. Common Stock
BKI
+$2.78M
3
VMW
VMware, Inc
VMW
+$2.72M
4
RPTX
Repare Therapeutics
RPTX
+$1.95M
5
COGT icon
Cogent Biosciences
COGT
+$1.63M

Top Sells

Rank Stock Value
1
COHR
Coherent Inc
COHR
+$3.62M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$2.96M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$2.37M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$1.8M
5
DYN icon
Dyne Therapeutics
DYN
+$1.6M

Sector Composition

Rank Sector Weight
1 Healthcare 46.35%
2 Technology 22.42%
3 Financials 15.33%
4 Communication Services 4.08%
5 Consumer Discretionary 3.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
26
Fate Therapeutics
FATE
$318M
$2.5M 1.43%
111,545
-7,233
-6% -$209K
NVCR icon
27
NovoCure
NVCR
$2.03B
$2.13M 1.22%
28,007
– –
VRDN icon
28
Viridian Therapeutics
VRDN
$2.68B
$2.1M 1.2%
102,372
+57,333
+127% +$1.03M
CPARU
29
DELISTED
Catalyst Partners Acquisition Corp. Unit
CPARU
$1.98M 1.13%
200,000
– –
RCUS icon
30
Arcus Biosciences
RCUS
$3.68B
$1.87M 1.07%
71,650
– –
CRNX icon
31
Crinetics Pharmaceuticals
CRNX
$8.94B
$1.81M 1.03%
92,047
+59,099
+179% +$1.21M
COGT icon
32
Cogent Biosciences
COGT
$6.66B
$1.77M 1.01%
+118,935
New +$1.63M
KDNY
33
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.64M 0.94%
83,551
+32,717
+64% +$656K
BMEA icon
34
Biomea Fusion
BMEA
$95M
$1.42M 0.81%
144,727
– –
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
$1.38M 0.79%
395,332
– –
GBIO
36
DELISTED
Generation Bio
GBIO
$1.32M 0.76%
24,899
– –
DYN icon
37
Dyne Therapeutics
DYN
$4.96B
$1.3M 0.74%
102,431
-139,436
-58% -$1.6M
GOSS icon
38
Gossamer Bio
GOSS
$89.9M
$1.16M 0.66%
96,795
– –
RLMD icon
39
Relmada Therapeutics
RLMD
$471M
$1.11M 0.64%
30,063
+570
+2% +$15.8K
CGEM icon
40
Cullinan Oncology
CGEM
$1.25B
$1.02M 0.59%
+79,918
New +$1.08M
EWTX icon
41
Edgewise Therapeutics
EWTX
$4.86B
$1.02M 0.58%
103,462
– –
DBC icon
42
Invesco DB Commodity Index Tracking Fund
DBC
$1.72B
$1.01M 0.58%
42,396
– –
ASND icon
43
Ascendis Pharma A/S
ASND
$16.7B
$1.01M 0.58%
9,780
+2,338
+31% +$222K
ANAB icon
44
AnaptysBio
ANAB
$1.69B
$944K 0.54%
36,987
+3,884
+12% +$91K
MSFT icon
45
Microsoft
MSFT
$3.74T
$929K 0.53%
3,988
– –
SNDX icon
46
Syndax Pharmaceuticals
SNDX
$1.81B
$892K 0.51%
+37,104
New +$832K
NBIX icon
47
Neurocrine Biosciences
NBIX
$16.5B
$889K 0.51%
8,373
+4,606
+122% +$467K
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.89B
$885K 0.51%
8,009
-1,572
-16% -$158K
ACAD icon
49
Acadia Pharmaceuticals
ACAD
$5.09B
$872K 0.5%
53,318
+13,418
+34% +$217K
ALNY icon
50
Alnylam Pharmaceuticals
ALNY
$29.3B
$848K 0.48%
4,239
-749
-15% -$143K
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return

HighVista Strategies's Q3 2022 Portfolio in Review

As of Q3 2022, HighVista Strategies held 129 positions worth $175M, up 5.7% from $166M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

HighVista Strategies deployed $6.42M of net new capital in Q3 2022, opening 19 new positions and adding to 30 existing holdings. Its largest new stake was Nielsen Holdings plc: 114,200 shares worth $3.17M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 46% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $1.6M trimmed.

  • HighVista Strategies's largest Q3 2022 buy was Nielsen Holdings plc: 114,200 shares worth $3.17M.
  • HighVista Strategies added most to Repare Therapeutics in Q3 2022, an estimated $1.95M increase.
  • HighVista Strategies's biggest Q3 2022 reduction was Dyne Therapeutics, cutting an estimated $1.6M.
  • HighVista Strategies fully exited Coherent Inc in Q3 2022, selling an estimated $3.62M.
  • HighVista Strategies's ten largest holdings make up 37% of its $175M portfolio in Q3 2022.
  • HighVista Strategies opened 19 new positions and closed 16 in Q3 2022.
  • HighVista Strategies's portfolio value rose 5.7% quarter-over-quarter to $175M.

Based on HighVista Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.